company background image
CYRX

CryoportNasdaqCM:CYRX Stock Report

Market Cap

US$3.2b

7D

8.6%

1Y

41.4%

Updated

27 Sep, 2021

Data

Company Financials +
CYRX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CYRX Overview

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Cryoport Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cryoport
Historical stock prices
Current Share PriceUS$70.07
52 Week HighUS$39.10
52 Week LowUS$84.97
Beta0.87
1 Month Change15.63%
3 Month Change6.34%
1 Year Change41.41%
3 Year Change455.67%
5 Year Change3,438.89%
Change since IPO-36.87%

Recent News & Updates

Shareholder Returns

CYRXUS Medical EquipmentUS Market
7D8.6%-0.8%2.0%
1Y41.4%32.6%32.8%

Return vs Industry: CYRX exceeded the US Medical Equipment industry which returned 32.6% over the past year.

Return vs Market: CYRX exceeded the US Market which returned 32.8% over the past year.

Price Volatility

Is CYRX's price volatile compared to industry and market?
CYRX volatility
CYRX Beta0.87
Industry Beta0.88
Market Beta1

Stable Share Price: CYRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: CYRX's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999650Jerry Sheltonhttps://www.cryoport.com

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle; and Cryoport Express Advanced Therapy Shippers that provides verification processes to biopharma companies. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems.

Cryoport Fundamentals Summary

How do Cryoport's earnings and revenue compare to its market cap?
CYRX fundamental statistics
Market CapUS$3.22b
Earnings (TTM)-US$78.39m
Revenue (TTM)US$169.01m

19.1x

P/S Ratio

-41.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYRX income statement (TTM)
RevenueUS$169.01m
Cost of RevenueUS$93.11m
Gross ProfitUS$75.90m
ExpensesUS$154.30m
Earnings-US$78.39m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.70
Gross Margin44.91%
Net Profit Margin-46.39%
Debt/Equity Ratio17.9%

How did CYRX perform over the long term?

See historical performance and comparison

Valuation

Is Cryoport undervalued compared to its fair value and its price relative to the market?

5.02x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: CYRX ($70.07) is trading above our estimate of fair value ($21.53)

Significantly Below Fair Value: CYRX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CYRX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: CYRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYRX is overvalued based on its PB Ratio (5x) compared to the US Medical Equipment industry average (4.7x).


Future Growth

How is Cryoport forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

69.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYRX's revenue (23.5% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: CYRX's revenue (23.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CYRX's Return on Equity is forecast to be low in 3 years time (2.4%).


Past Performance

How has Cryoport performed over the past 5 years?

-47.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYRX is currently unprofitable.

Growing Profit Margin: CYRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYRX is unprofitable, and losses have increased over the past 5 years at a rate of 47% per year.

Accelerating Growth: Unable to compare CYRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYRX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (40.5%).


Return on Equity

High ROE: CYRX has a negative Return on Equity (-4.92%), as it is currently unprofitable.


Financial Health

How is Cryoport's financial position?


Financial Position Analysis

Short Term Liabilities: CYRX's short term assets ($411.8M) exceed its short term liabilities ($38.2M).

Long Term Liabilities: CYRX's short term assets ($411.8M) exceed its long term liabilities ($139.1M).


Debt to Equity History and Analysis

Debt Level: CYRX's debt to equity ratio (17.9%) is considered satisfactory.

Reducing Debt: CYRX's debt to equity ratio has increased from 17% to 17.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CYRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Cryoport current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Jerry Shelton (76 yo)

8.83yrs

Tenure

US$5,484,107

Compensation

Mr. Jerrell W. Shelton, also known as Jerry, has been the Chief Executive Officer and President of CryoPort, Inc. since November 5, 2012 and has been its Chairman of the Board since October 2015. Mr. Shelt...


CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD5.48M) is about average for companies of similar size in the US market ($USD5.22M).

Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CYRX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: CYRX's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.


Top Shareholders

Company Information

Cryoport, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Cryoport, Inc.
  • Ticker: CYRX
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$3.225b
  • Shares outstanding: 46.02m
  • Website: https://www.cryoport.com

Number of Employees


Location

  • Cryoport, Inc.
  • 112 Westwood Place
  • Suite 350
  • Brentwood
  • Tennessee
  • 37027
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 23:02
End of Day Share Price2021/09/27 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.